Brief: Kairos Pharma Reports Positive Interim Phase 2 Data For ENV105 In Advanced Prostate Cancer, PFS Over One Year
18/09/2025 13:15
Sept 18 (Reuters) - Kairos Pharma Ltd KAPA.A: KAIROS PHARMA ANNOUNCES POSITIVE INTERIM EFFICACY ANALYSIS OF PHASE 2 TRIAL OF ENV105 IN ADVANCED PROSTATE CANCER WITH MEDIAN PROGRESSION FREE SURVIVAL OF OVER ONE YEAR Source text: ID:nBw2VKZnYa Further company coverage: KAPA.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kairos Pharma
See all newsBrief: Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbimed And Torrey Pines Investment-Backed Celyn Therapeutics
Brief: Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition
Brief: Kairos Pharma To Present Positive Safety And Efficacy Data From Phase 2 Prostate Cancer Trial At Esmo 2025
Brief: Kairos Pharma Reports Positive Interim Phase 2 Data For ENV105 In Advanced Prostate Cancer, PFS Over One Year
Brief: Kairos Pharma Announces Virtual KOL Event To Provide Perspectives On ENV105 Interim Efficacy Results In Advanced Prostate Cancer